No headlines found.
No press releases found.
No news found.
Alaunos Therapeutics Inc is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products. The company focuses on evaluating the impact of ALN1001, its primary program, and its derivatives on lipid deposition and gene expression. It aims to develop an oral obesity compound that addresses many of the shortcomings of injectable GLP-1 receptor agonists including preserving lean muscle mass.
Alaunos Therapeutics trades on the NASDAQ stock market under the symbol TCRT.
As of December 15, 2025, TCRT stock price climbed to $4.34 with 36,205 million shares trading.
TCRT has a beta of -2.15, meaning it tends to be less sensitive to market movements. TCRT has a correlation of 0.10 to the broad based SPY ETF.
TCRT has a market cap of $9.69 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, TCRT traded as high as $128.94 and as low as $1.31.
The top ETF exchange traded funds that TCRT belongs to (by Net Assets): VXF.
TCRT has outperformed the market in the last year with a price return of +108.7% while the SPY ETF gained +13.9%. TCRT has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +87.9% and +29.9%, respectively, while the SPY returned +3.9% and -0.4%, respectively.
TCRT support price is $3.94 and resistance is $4.58 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TCRT shares will trade within this expected range on the day.
